Cancer Screening

Non-invasive blood and urine-based cancer screening tests, including FDA-approved tests for colorectal cancer and bladder cancer risk stratification.

Cxbladder® Detect is a urine genomic test designed to improve workflow efficiency in urological care. It is optimised for patients presenting with microhaematuria and helps to de-intensify the clinical work-up in those with a low-probability result. It also resolves atypical urine cytology and equivocal cystoscopy findings.

Urine genomic test for microhaematuria risk stratification. Reduces unnecessary cystoscopy. Resolves atypical cytology.

Cxbladder® Detect | Microhaematuria Risk Stratification Test | Codex Genetics

Optimised for microhaematuria risk stratification. Resolves atypical cytology and equivocal cystoscopy findings, reducing unnecessary invasive investigations.

Cxbladder® Detect

Cxbladder® Triage is a non-invasive urine genomic test that measures the expression of five biomarker genes (CDC2, IGFBP5, HOXA13, MDK, CXCR2) to determine the likelihood of urothelial cancer. It is recommended in the 2020 American Urological Association (AUA) Microhaematuria Guideline as the first and only urine-based genomic biomarker test supported by Level A Evidence. Cxbladder® Triage Plus is an improved version of the test, which also includes 6 DNA SNVs from 2 genes (FGFR3/TERT)

AUA Level A Evidence urine genomic test for haematuria risk stratification. Non-invasive bladder cancer screening. 

Cxbladder® Triage | Urine Genomic Bladder Cancer Test | Codex Genetics

Genomic urine test to stratify patients presenting with haematuria. The first and only urine-based test included in the AUA Microhaematuria Guideline with Level A Evidence.

Cxbladder® Triage

Guardant Shield™ is a qualitative, blood-based colorectal cancer screening test that analyzes cell-free DNA (cfDNA) signals from plasma. It is intended for individuals at average colorectal cancer risk who are 45 years or older.

A positive Shield result requires follow-up colonoscopy. A negative result does not rule out colorectal cancer or advanced adenoma, and routine guideline-based screening should continue at recommended intervals.

Qualitative blood-based CRC screening test for average-risk adults age 45+.

Guardant Shield™ | Blood-Based Colorectal Cancer Screening (45+)

Qualitative blood-based IVD for colorectal cancer screening in average-risk adults age 45+

Guardant Shield™

癌症筛查

透过液态活检及其他非侵入性技术，实现癌症的早期检测与风险评估。

Cxbladder® Detect 是一项尿液基因检测，旨在提升泌尿科照护流程效率。该检测特别针对微血尿患者优化，对低概率结果者可协助降低临床检查强度，并可用于澄清非典型尿细胞学及界线性膀胱镜结果。

用于微血尿风险分层的尿液基因检测。降低不必要膀胱镜，并协助澄清非典型细胞学结果。

Cxbladder® Detect｜微血尿风险分层检测｜Codex Genetics

针对微血尿风险分层优化的尿液基因检测。可协助澄清非典型尿细胞学与界线性膀胱镜结果，降低不必要的侵入性检查。

Cxbladder® Triage 是一项非侵入性尿液基因检测，通过测量五个生物标记基因（CDC2、IGFBP5、HOXA13、MDK、CXCR2）的表达，评估尿路上皮癌的可能性。该检测已纳入 2020 年美国泌尿外科协会（AUA）微血尿指引，为首个且目前唯一获 A 级证据支持的尿液基因组生物标记测试。Cxbladder® Triage Plus 为其升级版本，额外整合 2 个基因（FGFR3、TERT）的 6 个 DNA SNV。

具 AUA A 级证据支持的血尿风险分层尿液基因检测。非侵入性评估膀胱癌风险。

Cxbladder® Triage｜血尿风险分层尿液基因检测｜Codex Genetics

用于血尿患者风险分层的尿液基因检测。该检测为首个且目前唯一纳入 AUA 微血尿指引并具 A 级证据支持的尿液基因组生物标记测试。

Guardant Shield™ 是一项定性血液型结直肠癌筛查检测，通过血浆中的游离 DNA（cfDNA）信号进行分析。适用于 45 岁以上、属于结直肠癌平均风险的人群。

Shield 阳性结果需进一步接受结肠镜检查。阴性结果不代表可排除结直肠癌或进展期腺瘤，仍应按指南建议间隔持续规律筛查。

适用于 45 岁以上平均风险成人的定性血液型结直肠癌筛查

Guardant Shield™｜血液型结直肠癌筛查（45+）

定性血液体外诊断（IVD）检测，用于 45 岁以上平均风险成人之结直肠癌筛查；阳性结果需安排结肠镜随访。

癌症篩查

透過液態活檢及其他非侵入性技術，實現癌症的早期檢測與風險評估。

Cxbladder® Detect 是一項尿液基因檢測，旨在提升泌尿科照護流程效率。此檢測特別針對微血尿患者優化，對低機率結果者可協助降低臨床檢查強度，並可用於釐清非典型尿細胞學及界線性膀胱鏡結果。

用於微血尿風險分層的尿液基因檢測。降低不必要膀胱鏡，並協助釐清非典型細胞學結果。

Cxbladder® Detect｜微血尿風險分層檢測｜Codex Genetics

針對微血尿風險分層優化的尿液基因檢測。可協助釐清非典型尿細胞學與界線性膀胱鏡結果，降低不必要的侵入性檢查。

Cxbladder® Triage 是一項非侵入性尿液基因檢測，透過量測五個生物標記基因（CDC2、IGFBP5、HOXA13、MDK、CXCR2）的表現，評估尿路上皮癌的可能性。該檢測已納入 2020 年美國泌尿外科學會（AUA）微血尿指引，為首個且目前唯一獲 A 級證據支持的尿液基因體生物標記測試。Cxbladder® Triage Plus 為其升級版本，額外整合 2 個基因（FGFR3、TERT）的 6 個 DNA SNV。

具 AUA A 級證據支持之血尿風險分層尿液基因檢測。非侵入性評估膀胱癌風險。

Cxbladder® Triage｜血尿風險分層尿液基因檢測｜Codex Genetics

用於血尿患者風險分層的尿液基因檢測。此檢測為首個且目前唯一納入 AUA 微血尿指引並具 A 級證據支持的尿液基因體生物標記測試。

Guardant Shield™ 是一項定性血液型結直腸癌篩檢檢測，透過血漿中的游離 DNA（cfDNA）訊號進行分析。適用於 45 歲以上、屬於結直腸癌平均風險的人群。

Shield 陽性結果需進一步接受大腸鏡檢查。陰性結果不代表可排除結直腸癌或進階腺瘤，仍應依指引建議之間隔持續規律篩檢。

適用於 45 歲以上平均風險成人的定性血液型結直腸癌篩檢

Guardant Shield™｜血液型結直腸癌篩檢（45+）

定性血液體外診斷（IVD）檢測，用於 45 歲以上平均風險成人之結直腸癌篩檢

Cancer Screening

Available Tests

Cxbladder® Detect

Cxbladder® Triage

Guardant Shield™

Quick Links

Resources

Newsletter